Evaluation of CCR2 in Patients Post Myocardial Infarction
Status:
Recruiting
Trial end date:
2025-11-24
Target enrollment:
Participant gender:
Summary
To determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the
cellular level in the myocardium for individuals who have suffered a heart attack or who have
other inflammatory heart disease.